Compare Harley-Davidson Inc (HOG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Medpace Holdings Inc — how do they compare? Harley-Davidson Inc trades at $26.85 (market cap $2.78B), while Medpace Holdings Inc trades at $616.43 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 6.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.8% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Medpace Holdings Inc for 14 Days on average.
| HOG | MEDP | |
|---|---|---|
Market Cap | $2.78B | $16.82B |
Volume | 2,966,389 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $630.19 |
52-Week Low | $17.19 | $393.42 |
Typical Hold Time | 92 Days | 14 Days |
Enterprise Value | $3.20B | $16.44B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.83, down 0.45% with a bullish technical signal and mixed earnings performance. The stock shows attractive valuation metrics with P/E of 14.86 and P/S of 0.72, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. Recent Q2 2026 earnings beat expectations with $0.75 EPS versus $0.645 expected, though Q1 and Q4 2025 results missed targets. The company maintains a dividend payout with recent $0.1875 declaration.
Outlook remains cautious as revenue declines and margin compression continue, though valuation appears reasonable. Key risks include tariff exposure, competitive pressures, and ongoing revenue contraction. Analyst consensus targets $28.50 with mixed sentiment (27.78% Buy, 61.11% Hold). The stock offers value characteristics but faces fundamental headwinds requiring careful monitoring of turnaround execution.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
